Driven by the high demand for sensitive and specific tools for optical sensing and imaging, bioprobes with various working mechanisms and advanced functionalities are flourishing at an incredible speed. Conventional fluorescent probes suffer from the notorious effect of aggregation-caused quenching that imposes limitation on their labelling efficiency or concentration to achieve desired sensitivity. The recently emerged fluorogens with an aggregation-induced emission (AIE) feature offer a timely remedy to tackle the challenge. Utilizing the unique properties of AIE fluorogens (AIEgens), specific light-up probes have been constructed through functionalization with recognition elements, showing advantages such as low background interference, a high signal to noise ratio and superior photostability with activatable therapeutic effects. In this tutorial review, we summarize the recent progress in the development of specific AIEgen-based light-up bioprobes. Through illustration of their operation mechanisms and application examples, we hope to provide guidelines for the design of more advanced AIE sensing and imaging platforms with high selectivity, great sensitivity and wide adaptability to a broad range of biomedical applications.

The efficiency of the intersystem crossing process can be improved by reducing the energy gap between the singlet and triplet excited states (ΔE ST), which offers the opportunity to improve the yield of the triplet excited state.

No abstract

The blood–brain barrier (BBB) is a critical biological structure that prevents damage to the brain and maintains its bathing microenvironment. However, this barrier is also the obstacle to deliver beneficial drugs to treat CNS (central nervous system) diseases. Many efforts have been made for improvement of delivering drugs across the BBB in recent years to treat CNS diseases. In this review, the anatomical and functional structure of the BBB is comprehensively discussed. The mechanisms of BBB penetration are summarized, and the methods and effects on increasing BBB permeability are investigated in detail. It also elaborates on the physical, chemical, biological and nanocarrier aspects to improve drug delivery penetration to the brain and introduces some specific drug delivery effects on BBB permeability.

No abstract

Fluorogens with aggregation-induced emission (AIE) characteristics have attracted intensified research interest in biosensing applications, and those with specific targeting ability are especially desirable. In this work, we designed and synthesized an AIE fluorescent probe by functionalizing a tetraphenylethylene (TPE) fluorogen with two phosphate groups (TPE-phos) for the detection of alkaline phosphatase (ALP) and its enzymatic activity based on the specific interaction between the probe and ALP. The probe is virtually nonfluorescent in aqueous media due to good water solubility. In the presence of ALP, the phosphate groups are cleaved through enzymatic hydrolysis, yielding a highly fluorescent product as a result of activated AIE process. This light-up probe shows excellent selectivity toward ALP among a group of proteins. The detection limit is found to be 11.4 pM or 0.2 U L(-1) in Tris buffer solution with a linear quantification range of 3-526 U L(-1). The assay is also successfully performed in diluted serum with a linear range up to 175 U L(-1), demonstrating its potential application in clinical analysis of ALP levels in real samples. Furthermore, by conducting kinetic analysis of the enzyme using TPE-phos as the substrate, the kinetic parameter kcat/KM is determined to be 5.1×10(5) M(-1) s(-1), indicating a high efficiency of the substrate.

Here, a strategy for synthesizing monodisperse AgAu alloy nanoparticles whereby particle attributes such as morphology, composition, size, and surface chemistry may be independently controlled, varied, and customized is presented. The synthesis uses a multi‐step procedure to deliver control of morphology, size, and composition in discrete and independent steps. Specifically Ag nanoparticles with the same morphology but different sizes are first prepared by the chemical reduction of Ag ions. A digestive ripening post‐treatment followed by seed‐mediated growth is then applied to narrow the size distribution and to vary the particle size. Monodisperse AgAu alloy nanoparticles are then formed by a replacement reaction with HAuCl4. Both single‐crystalline truncated octahedral (TO) AgAu alloy nanoparticles and icosahedral multiply twinned particles can be easily prepared by this procedure. By using truncated octahedrons as the model morphology, the syntheses of nanoparticles with the same size but different compositions, of nanoparticles with the same composition but variable sizes, and of nanoparticles with different surface chemistry are demonstrated and discussed in detail. Because of the shape and size monodispersity, all of the as‐synthesized AgAu alloy nanoparticles easily form superlattices on a solid substrate upon slow evaporation of the solvent. The packing pattern of the nanoparticles is strongly dependent on the native morphology of the nanoparticles.

Cu2O-reduced graphene oxide nanocomposite (Cu2O-RGO) was used to modify glassy carbon electrodes (GCE), and applied for the determination of dopamine (DA). The microstructure of Cu2O-RGO nanocomposite material was characterized by scanning electron microscope. Then the electrochemical reduction condition for preparing Cu2O-RGO/GCE and experimental conditions for determining DA were further optimized. The electrochemical behaviors of DA on the bare electrode, RGO- and Cu2O-RGO-modified electrodes were also investigated using cyclic voltammetry in phosphate-buffered saline solution (PBS, pH 3.5). The results show that the oxidation peaks of ascorbic acid (AA), dopamine (DA), and uric acid (UA) could be well separated and the peak-to-peak separations are 204 mV (AA-DA) and 144 mV (DA-UA), respectively. Moreover, the linear response ranges for the determination of 1 × 10−8 mol/L~1 × 10−6 mol/L and 1 × 10−6 mol/L~8 × 10−5 mol/L with the detection limit 6.0 × 10−9 mol/L (S/N = 3). The proposed Cu2O-RGO/GCE was further applied to the determination of DA in dopamine hydrochloride injections with satisfactory results.